The global viral vector and plasmid DNA manufacturing market is estimated to grow from USD 937 million in the current year to USD 2.16 billion by 2035, at a CAGR of 9.73% during the forecast period, till 2035.
To satisfy the increasing need for vectors, the sector has launched various process improvements. Interestingly, Corning Life Sciences has created high-density cell culture systems, such as HYPERStack and CellSTACKs, which utilize gas-permeable film technology to improve vector yields. The firm has additionally launched automation systems to enhance workflows, decrease manual involvement, and speed up production schedules. These advancements in technology have generated momentum for more efficient, reliable, and economical vector production globally.
Currently, more than 300 players from both industry and non-industry sectors worldwide are engaged in efforts to back the growing pipeline of cell therapies, gene therapies, and vector-based vaccines, according to the viral vectors and plasmid DNA manufacturing market report. The expansion in this sector is additionally driven by investments, strategic partnerships, and facility expansions, demonstrating a solid dedication to addressing production challenges. These advancements indicate that manufacturing for both viral and non-viral vectors is set for significant growth, positioning them as essential contributors to the upcoming wave of genetic therapies.
Viral Vector and Plasmid DNA Manufacturing Market
The market sizing and opportunity analysis has been segmented across the following parameters:
Scale of Operation
- Preclinical
- Clinical
- Commercial
Application Area
- Cell Therapies
- Gene Therapies
- Vaccines
Type of Vector Manufactured
- AAV Vectors
- Adenoviral Vectors
- Lentiviral Vectors
- Retroviral Vectors
- Non-viral Vectors
- Other Vectors
Therapeutic Area
- Oncological Disorders
- Rare Disorders
- Immunological Disorders
- Neurological Disorders
- Sensory Disorders
- Metabolic Disorders
- Blood Disorders
- Musculoskeletal Disorders
- Infectious Diseases
- Ophthalmic Disorders
- Other Disorders
Type of Manufacturer
- In-house Manufacturers
- Contract Manufacturing Organizations
Geographical Regions
- North America
- Europe
- Asia-Pacific
- Middle East and North Africa
- Latin America
VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET: GROWTH AND TRENDS
Viral and non-viral vectors have become essential instruments for transferring genetic material into target cells, constituting the foundation of contemporary cell and gene therapies. In recent years,, approximately 30 therapies utilizing viral vectors have gained global regulatory approval, with more than 500 candidates currently in clinical trials in the US. The increase in approvals and continuing research has driven the need for extensive viral vector production. Nonetheless, this field encounters numerous challenges, such as risks of immunogenicity and the intricate character of viral vector analysis. To address these challenges, developers are progressively investigating the possibilities of non-viral vectors as more secure and scalable options.To satisfy the increasing need for vectors, the sector has launched various process improvements. Interestingly, Corning Life Sciences has created high-density cell culture systems, such as HYPERStack and CellSTACKs, which utilize gas-permeable film technology to improve vector yields. The firm has additionally launched automation systems to enhance workflows, decrease manual involvement, and speed up production schedules. These advancements in technology have generated momentum for more efficient, reliable, and economical vector production globally.
Currently, more than 300 players from both industry and non-industry sectors worldwide are engaged in efforts to back the growing pipeline of cell therapies, gene therapies, and vector-based vaccines, according to the viral vectors and plasmid DNA manufacturing market report. The expansion in this sector is additionally driven by investments, strategic partnerships, and facility expansions, demonstrating a solid dedication to addressing production challenges. These advancements indicate that manufacturing for both viral and non-viral vectors is set for significant growth, positioning them as essential contributors to the upcoming wave of genetic therapies.
VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET: KEY INSIGHTS
The report delves into the current state of the global viral vector and plasmid DNA manufacturing market and identifies potential growth opportunities within industry. Some key findings from the report include:- Presently, over 130 industry players claim to have the necessary capabilities to manufacture different types of viral vectors for in-house requirements and / or contract service engagements.
- The current viral vector manufacturing market landscape features the presence of around 70% contract manufacturers; among these, about 20% players have capability to manufacture all types of viral vectors.
- Close to 50% of the companies in this domain have the capability to operate across all three scales of operation, namely preclinical, clinical and commercial.
- We have mapped the locations of facilities established by different vector manufacturers worldwide; notably, Europe emerged as the prominent viral and non-viral vector manufacturing hub.
- Around 85% of the non-industry players are engaged in the manufacturing of AAV vectors; further, close to 80% of the organizations are focused on manufacturing vectors for gene therapy applications.
- Majority (43%) of the technologies are being utilized for manufacturing vectors that can be used for the treatment of neurological disorders, followed by oncological disorders (30%).
- Presently, close to 150 expansions have been undertaken by various players, underscoring the growing interest and investment in the vector-based cell and gene therapy domain.
- The rising interest in this domain is also reflected by the number of partnerships that have been inked in the recent past, involving both international and local stakeholders.
- In order to increase efficiency and optimize the manufacturing processes, several vector and gene therapy innovators are anticipated to forge strategic alliances with vector and gene therapy manufacturers.
- Over 65% of the global installed gene therapy and vector manufacturing capacity is dedicated to viral vector manufacturing; ~55% of viral vector manufacturing capacity is installed in the facilities located in North America.
- Given that there are several types of vectors being evaluated across various stages of development, the demand for such vectors is anticipated to rise significantly over the next decade.
- The overall opportunity associated with vector manufacturing domain is anticipated to grow at the CAGR of 9.73%; it is likely to be well distributed across different, scales of operation, types of vectors and geographical regions.
- Over the long term, vector-based therapies for oncological disorders, which hold more than 60% market share are expected to drive the growth of this market.
VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET: KEY SEGMENTS
Clinical Segment Occupies the Highest Revenue Share in the Viral Vector and Plasmid DNA Manufacturing Market
The market is segmented across various scales of operation such as preclinical, clinical and commercial. As per viral vector and plasmid DNA manufacturing market analysis, in the current year, the clinical segment occupies the higher market share (50%). This is a result of the high demand from numerous ongoing gene and cell therapy clinical trials. It is worth mentioning that the commercial stage segment is likely to witness a significant growth rate with a CAGR of 13% during the forecast period. This results from the advancing cell and gene therapy field, where the majority of therapies are in later development stages and are expected to enter the market in short-term.Lentiviral Vector Segment Holds the Largest Viral Vector and Plasmid DNA Manufacturing Market Share
In terms of the type of vector manufactured, the overall market includes AAV vectors, adenoviral vectors, lentiviral vectors, retroviral vectors, non-viral vectors and other vectors. In the current year, lentiviral vector segment occupies the higher market share (25%). Several lentiviral vector based gene therapies and cell therapies are currently in the late stage of clinical development. Further, the market is likely to witness a substantial increase in the share of AAV vectors market share, growing at a CAGR of 13% during the forecast period. This is ascribed to advantages offered by AAV vectors, such as efficient transduction of various cell types and their ability to deliver large amounts of DNA.Gene Therapy is Likely to Capture Majority of the Viral Vector and Plasmid DNA Manufacturing Market Share
Based on application area, the overall marker includes cell therapy, gene therapy and vaccine. Currently, vectors that are used in gene therapy segments occupy the highest market share (49%). This is due to the rising number of approved gene therapies for multiple indications, which has substantially increased the demand for high-quality vector production. Further, the market is likely to witness a substantial increase in the share of vectors that are used for cell therapy manufacturing, growing at a CAGR of 11% during the forecast period. This trend is due to an increasing number of therapies that are currently in clinical trials.Oncological Disorders Segment Holds the Largest Viral Vector and Plasmid DNA Manufacturing Market Share
As per viral vector and plasmid DNA manufacturing market forecast, in the current year, vector-based therapies for the treatment of oncological disorders occupy the highest market share (47%), due to the growing incidence of such disorders across the globe. Further, vector-based therapies for the treatment of ophthalmic disorders are likely to grow at a CAGR of 31% during the forecast period. This is because of the growing number of approvals for cell and gene therapies for eye disorders.Contract Manufacturing Segment is Likely to Dominate the Viral Vector and Plasmid DNA Manufacturing Market
This segment highlights the distribution of market across various types of manufacturers, such as contract manufacturing and in-house manufacturing. Currently, contract manufacturer segment (57%) is likely to dominate the market and is expected to grow at a higher CAGR (11%) during the forecast period. This trend arises from the ability of CMOs to provide scalability and flexibility, allowing them to quickly adjust to evolving manufacturing needs and handle increasing production demands.Asia-Pacific and Middle East and North Africa is Likely to Propel the Growth of the Viral Vector and Plasmid DNA Manufacturing Market
Currently, North America (54%) captures the highest market share. This results from the developed healthcare system and research environment in North America. In contrast, the Asia-Pacific, and Middle East and North Africa markets are expected to expand at a comparatively higher CAGR of 11% each, during the forecast period. This is attributed to the growing prevalence of chronic conditions such as neurological conditions, genetic conditions, and rare illnesses and the heightened need for efficient and sophisticated treatments.Primary Research Overview
Discussions with multiple stakeholders in this domain influenced the opinions and insights presented in this study. The market report includes transcripts of the following other third-party discussions:
- Chief Executive Officer, mid-sized company, Netherlands
- Chief Executive Officer and Chief Scientific Officer, small company, Germany
- Former Executive and Scientific Director, small company, Belgium
- Co-Founder and President, mid-sized company, France
- Former Director, Netherlands-based company
- Director, Massachusetts-based organization
- Former Scientific Director, France-based organization
- Former Managing Director, small company, Japan
- Scientific Director, small company, US
- Key Account Management, mid-sized company, Germany
- Head of Project Management, small company, Germany
- Director of Business Development, small company, US
- ATMP Key Account Manager, France-based organization
- Chief Scientific Officer, small company, France
- Director of Marketing and Technical Support, mid-sized company, France
- Head of Communications, mid-sized company, Spain
- Independent Consultant
Example Players in the Viral Vector and Plasmid DNA Manufacturing Market
- Advanced BioScience Laboratories
- AGC Biologics
- Aldevron
- Celonic
- Catalent Biologics
- Charles River Laboratories
- Novartis
- Oxford BioMedica
VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET: RESEARCH COVERAGE
- Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the viral vector and plasmid DNA manufacturing market, focusing on key market segments, including [A] scale of operation, [B] type of vector manufactured, [C] application area, [D] therapeutic area, [E] type of manufacturer and [F] geographical regions.
- Market Landscape 1: A detailed assessment of the viral vector and plasmid DNA manufacturing market based on several relevant parameters, such as [A] year of establishment, [B] company size, [C] location of headquarters, [D] type of product manufactured, [E] location of manufacturing facility, [F] type of manufacturer, [G] scale of operation, and [H] application area.
- Market Landscape 2: A detailed assessment of the industry players engaged in manufacturing plasmid DNA and gene therapies based on several relevant parameters, such as [A] year of establishment, [B] company size, [C] location of headquarters, [D] type of product manufactured, [E] scale of operation, and [F] application area.
- Market Landscape 3: A detailed assessment of the non-industry players engaged in the manufacturing of viral, non viral and other novel types of vectors and gene therapies, based on relevant parameters such as [A] year of establishment, [B] location of vector manufacturing facility, [C] type of manufacturer, [D] scale of operation, [E] type of vector manufactured and [F] application area.
- Technology Landscape: An in-depth analysis of the technologies offered / developed by the companies engaged in this market, based on the [A] type of technology, [B] purpose of technology, [C] scale of, [D] type of vector, and [E] application area.
- Company Competitiveness Analysis: A comprehensive competitive analysis of key players engaged in manufacturing vectors and gene therapies, examining factors, such as [A] supplier strength [B] manufacturing strength and [C] service strength.
- Company Profiles: In-depth profiles of prominent players based in regions, namely North America, Europe and Asia-Pacific that are currently involved in the viral vector and plasmid DNA manufacturing market, focusing on [A] year of establishment, [B] location of headquarters, [C] product portfolio, [D] manufacturing facilities, [E] recent developments and [F] an informed future outlook.
- Partnerships and Collaborations An insightful analysis of the partnerships and collaborations established in gene therapy, non viral vector and viral vector manufacturing market based on various relevant parameters, including [A] year of partnership, [B] type of partnership, [C] type of partner and [D] most active players.
- Recent Expansions: An analysis of the recent expansions undertaken by various companies in order to augment their respective capabilities related to viral vector and non viral vector manufacturing, based on several parameters, such as [A] year of expansion, [B] type of expansion, [C] type of vector, [D] application area and [E] geographical location of the expansion.
- Strategic Partner Analysis: An insightful analysis evaluating the potential strategic partners (comparing vector based therapy developers and vector purification product developers) for vector and gene therapy product manufacturers, based on several parameters, such as [A] developer strength, [B] product strength, [C] type of vector, [D] therapeutic area and [E] pipeline strength.
- Emerging Vectors: An elaborate discussion on the emerging trends of other viral / non viral gene delivery approaches that are currently in research for the development of therapies involving genetic modification.
- Key Insights: An insightful analysis, highlighting the contemporary market trends in the plasmid DNA and viral vector manufacturing domain, based on relevant parameters, such as (type of vector, scale of operation and type of manufacturer), (type of vector and type of organization) and (location of headquarters and geographical location of key vector manufacturing hubs).
- Cost Price Analysis: An analysis of various factors that are likely to influence the pricing of vectors, featuring different models / approaches that may be adopted by product developers / manufacturers in order to decide the prices of their proprietary vectors.
- Go / No-Go Framework Analysis: An insightful go / no-go framework analysis, highlighting various factors that needs to be considered by viral vector and non viral vector manufacturing companies while deciding whether to manufacture their respective products in-house or engage the services of a CMO.
- Porter’s Five Forces Analysis: A qualitative analysis, highlighting the five competitive forces prevalent in gene therapy, non viral vector and viral vector manufacturing market, including [A] threats for new entrants, [B] bargaining power of drug developers, [C] bargaining power of vector and gene therapy manufacturers, [D] threats of substitute technologies and [E] rivalry among existing competitors.
- Capacity Analysis: An estimate of the overall, installed vector manufacturing capacity of industry players based on the information available in the public domain, and insights generated from both secondary and primary research. The analysis also highlights the distribution of global capacity by company size (small, mid-sized and large), location of headquarters (region) (North America, Europe, Asia Pacific and the rest of the world) and location of manufacturing facility.
- Demand Analysis: An in-depth analysis to estimate the current and future demand for viral vectors and non viral vectors, taking into consideration the marketed gene therapies and clinical studies evaluating vector-based therapies, based on various relevant parameters, such as [A] target patient population, [B] dosing frequency and [C] dose strength.
- Market Impact Analysis: An in-depth analysis of the factors that can impact the growth of gene therapy, non viral vector and viral vector manufacturing market. It also features identification and analysis of [A] key drivers, [B] potential restraints, [C] emerging opportunities, and [D] existing challenges.
KEY QUESTIONS ANSWERED IN THIS REPORT
- How many companies are currently engaged in this market?
- Which are the leading companies in this market?
- What is the current global capacity of developers?
- What factors are likely to influence the evolution of this market?
- What is the current and future market size?
- What is the CAGR of this market?
- How is the current and future market opportunity likely to be distributed across key market segments?
REASONS TO BUY THIS REPORT
- The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
- Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
- The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.
ADDITIONAL BENEFITS
- Complimentary PPT Insights Packs
- Complimentary Excel Data Packs Covering All Analytical Modules
- Up to 15% Complimentary Content Customization
- In-Depth Report Walkthrough with the Research Team
- Complimentary Report Update if the Report is 6+ Months Old
Table of Contents
1. PREFACE
2. RESEARCH METHODOLOGY
3. MARKET DYNAMICS
4. MACRO-ECONOMIC INDICATORS
6. INTRODUCTION
7. VIRAL VECTOR MANUFACTURERS (INDUSTRY PLAYERS): MARKET LANDSCAPE
8. PLASMID DNA MANUFACTURERS (INDUSTRY PLAYERS): MARKET LANDSCAPE
9. VIRAL VECTOR AND PLASMID DNA MANUFACTURERS (NON-INDUSTRY PLAYERS): MARKET LANDSCAPE
10. VECTOR MANUFACTURING TECHNOLOGIES LANDSCAPE
11. COMPANY COOMPETITIVENESS ANALYSIS
12. VECTOR MANUFACTURERS BASED IN NORTH AMERICA
13. VECTOR MANUFACTURERS BASED IN EUROPE
15. VECTOR MANUFACTURERS IN ASIA-PACIFIC
16. PORTER’S FIVE FORCES ANALYSIS
17. PARTNERSHIPS AND COLLAORATIONS
18. RECENT EXPANSIONS
19. STRATEGIC PARTNER ANAYSIS
20. EMERGING VECTORS
21. KEY INSIGHTS
22. COST PRICE ANALYSIS
23. OUTSOURCING: GO / NO-GO FRAMEWORK
24. CAPACITY ANALYSIS
25. DEMAND ANALYSIS
26. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES
27. GLOBAL VECTOR MANUFACTURING MARKET
28. VECTOR MANUFACTURING MARKET, BY SCALE OF OPERATION
29. VECTOR MANUFACTURING MARKET, BY TYPE OF VECTOR MANUFACTURED
30. VECTOR MANUFACTURING MARKET, BY APPLICATION AREA
31. VECTOR MANUFACTURING MARKET, BY THERAPEUTIC AREA
32. VECTOR MANUFACTURING MARKET, BY TYPE OF MANUFACTURER
33. VECTOR MANUFACTURING MARKET, BY GEOGRAPHICAL REGION
34. MARKET OPPORTUNITY ANALYSIS: NORTH AMERICA
35. MARKET OPPORTUNITY ANALYSIS: EUROPE
36. MARKET OPPORTUNITY ANALYSIS: ASIA-PACIFIC
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- 4D Molecular Therapeutics
- 53Biologics
- AavantiBios
- Abbott
- AbbVie
- Abeona Therapeutics
- Abintus Bio
- Accinov (acquired by Advanced BioScience Laboratories)
- Acucela
- AcuraBio
- Adaptimmune Therapeutics
- AdaptVac
- Addgene
- Aduro Biotech
- Advaccine
- Advanced BioScience Laboratories
- Advanced Biotherapeutics Consulting
- Advantagene
- Advaxis
- Advent
- Adverum Biotechnologies (formerly known as Avalanche Biotechnologies)
- Aevitas Therapeutics (a subsidiary of Fortress Biotech)
- AffyImmune Therapeutics
- AffyXel
- AGC Biologics
- Agilent Technologies
- Agilis Biotherapeutics (acquired by PTC Therapeutics)
- Ajinomoto Bio-Pharma Services
- Akdeniz University
- Akron Biotech
- Albumedix
- Aldevron
- Allele Biotechnology
- Allergan
- Allife Medicine
- Allogene Therapeutics
- Alma Bio Therapeutics
- AlphaVax
- ALSTEM
- Althea Technologies
- Altimmune
- Altor BioScience
- Altruist Biologics
- American Gene Technologies
- Amgen
- Amicus Therapeutics
- Ampersand Capital Partners
- AMSBIO
- Amsterdam BioTherapeutics Unit
- Amsterdam Molecular Therapeutics (acquired by uniQure)
- Anaeropharma Science
- Andelyn Biosciences
- Anemocyte
- AnGes
- Angionetics
- ANLBIO
- Annapurna Therapeutics (acquired by Avalanche Biotechnologies)
- apceth Biopharma (subsidiary of Hitachi Chemical)
- Applied Biological Materials
- Applied Genetic Technologies (AGTC)
- Applied StemCell
- Applied Viromics
- Arcellx
- ArcticZymes Technologies
- Areta International
- Arranta Bio (acquired by Recipharm)
- Aruvant Sciences
- ASC Therapeutics
- AskBio
- Asklepios BioPharmaceutical
- Astellas Pharma
- AstraZeneca
- Atara Biotherapeutics
- Atlantic Bio GMP (a subsidiary of Atlanpole Biotherapies)
- Atsena Therapeutics
- Audentes Therapeutics (acquired by Astella Pharma)
- Augusta University
- Aurigene Pharmaceutical Services
- Aurora Biopharma
- Autolus Therapeutics
- Avantor
- Avecia Biologics
- Avid Bioservices
- AVROBIO
- Axovant Gene Therapies
- Bamboo Therapeutics
- Batavia Biosciences
- Baylor College of Medicine
- BCM Families Foundation
- Beacon Biotherapeutics
- Beam Therapeutics
- Beckman Research Institute
- Beijing Biohealthcare Biotechnology
- Beijing Doing Biomedical
- Beijing Hetang Shenghua Medical Technology
- Beijing HuiNengAn Biotech
- Beijing Immunochina Medical Science & Technology
- Beijing Mario Biotech
- Beijing Sanwater Biological Technology
- Bellicum Pharmaceuticals
- Benitec Biopharma
- BIA Separations (acquired by Sartorius)
- Bioceltech Therapeutics
- BioCentriq (acquired by GC)
- BioCina
- Biogen
- Bio-Gene Technology
- BioInvent International
- Biological E.
- BioMarin Pharmaceuticals
- Biomay
- Biomiga
- Bionic Sight
- BioNTech Innovative Manufacturing Service (a subsidiary of BioNTech)
- Bio-Rad Laboratories
- BioReliance (a subsidiary of Merck KGaA)
- Bio-Synthesis
- BioVec Pharma
- Bioverativ
- Biovian
- BioVision
- Blue Sky BioServices (a subsidiary of LakePharma)
- bluebird bio (formerly known as Genetix Pharmaceuticals)
- BMS
- Boehringer Ingelheim BioXcellence
- BoYuan RunSheng Pharma
- Brain Neurotherapy Bio
- Brammer Bio (acquired by Thermo Fisher Scientific)
- Brazilian Biosciences National Laboratory (LNBio)
- Bristol Myers Squibb
- Cabaletta Bio
- Caltech
- Cambridge Gene Therapy
- Candel Therapeutics
- Capsugel
- Carina Biotech
- Carmine Therapeutics
- CARsgen Therapeutics
- Cartesian Therapeutics
- Casey Eye Institute
- Castle Creek Biosciences
- Catalent Biologics
- Celgene
- Cell and Gene Therapy Catapult
- Cell Biolabs
- Cellectis
- CellGenTech
- Cellular Biomedicine Group
- CellVec
- Celonic
- Celsion
- Celyad Oncology
- Center for Breakthrough Medicines
- Centre for Commercialization of Regenerative Medicine
- Centre for Process Innovation
- Cepham Life Sciences
- CEVEC Pharmaceuticals
- CG Oncology
- Charles River Laboratories
- Children’s Medical Research Institute (CMRI)
- Children's Hospital of Philadelphia
- China Immunotech Biotechnology
- Choroideremia Research Foundation
- Cincinnati Children's Hospital Medical Center
- City of Hope
- Clean Cells
- CLINO
- Cognate BioServices
- CoJourney
- CombiGene
- Copernicus Therapeutics
- Cornell University
- Creative Biogene
- Creative Biolabs
- CSL Behring
- Curia
- Cytiva (formerly known as GE Healthcare Life Sciences)
- CytoMed Therapeutics
- Cytovance Biologics
- Daiichi Sankyo
- Decibel
- Delphi Genetics
- Denali Therapeutics
- Department of Cell and Chemical Biology, Leiden University Medical Center
- DiNAMIQS
- DiNAQOR
- DNAtrix
- Duke University
- Durham
- Dyno Therapeutics
- Editas Medicine
- ElevateBio
- Elixirgen Scientific
- Emendo Biotherapeutics
- Emergent BioSolutions
- Emory University School of Medicine
- enGene
- Epeius Biotechnologies
- Errant Gene Therapeutics
- Erytech Pharma
- Esco Aster
- Esteve
- eTheRNA immunotherapies
- EUFETS
- Eureka Biotechnology
- Eurofins Genomics
- Eurofins Scientific
- ExcellGene
- Exothera
- Expression Therapeutics
- Eyevensys
- Fate Therapeutics
- FerGene
- FIMA
- FinVector (formerly known as Ark Therapeutics)
- Five Prime Therapeutics
- Flash Therapeutics
- Flexion Therapeutics
- Florida Biologix
- Forecyte Bio
- Forge Biologics
- Formula Pharmaceuticals
- Fortress Biotech
- Fosun Pharma
- Foundation Fighting Blindness
- Fraunhofer Institute for Toxicology and Experimental Medicine
- Freeline Therapeutics
- FUJIFILM Diosynth Biotechnologies
- Fundamenta Therapeutics
- G-CON Manufacturing
- GE Healthcare Life Sciences
- GEG Tech
- Genable Technologies
- GeneCopoeia
- GeneCure Biotechnologies
- GeneDetect
- GeneImmune Biotechnology
- Genelux
- GeneMedicine
- Genenta Science
- GeneOne Life Science
- Genethon
- GENEWIZ
- Genexine
- Genezen Laboratories
- GenIbet Biopharmaceuticals
- Genopis (acquired by Wacker Biotech)
- Genovac
- Genprex
- GenScript
- GenSight Biologics
- GenVec
- Gen-X
- Genzyme
- GeoVax Labs
- GIGA
- GlaxoSmithKline
- Gracell Biotechnologies
- Gradalis
- Green Cross LabCell
- Grousbeck Gene Therapy Center
- Guangdong Xiangxue Precision Medical Technology
- Guangdong Zhaotai InVivo Biomedicine
- Guangzhou Anjie Biomedical Technology
- Guangzhou FineImmune Biotechnology
- Gyroscope Therapeutics
- Hadassah Medical Organization
- HaemaLogiX
- HALIX
- Handl Therapeutics
- Hanmi Bio Plant (a subsidiary of Hanmi Pharm)
- Harvard Gene Therapy Initiative
- Hebei Senlang Biotechnology
- Heidelberg University Hospital
- Helixmith
- Hemera Biosciences
- Henan Hualong Biotechnology
- Herantis Pharma
- Hitachi Chemical Advanced Therapeutics Solutions
- Holostem Terapie Avanzate
- Homology Medicines
- Hong Kong Institute of Biotechnology
- Hookipa Biotech
- HORAMA
- Hrain Biotechnology
- Huadao biomedical
- Huapont Life Sciences
- Human Stem Cells Institute
- Hunan Zhaotai Yongren Medical Innovation
- Icahn School of Medicine at Mount Sinai
- iCAR Bio Therapeutics
- iCarTAB BioMed
- iCell Gene Therapeutics
- ID Pharma (formerly known as DNAVEC)
- IDT Biologika
- Ilya Pharma
- Immatics
- Immune Design
- Immune Technology
- Immunocore
- Immunomic Therapeutics
- Imperial Innovations
- Imperial Innovations
- Indiana University
- Innovative Cellular Therapeutics
- InnovaVector
- INOVIO Pharmaceuticals
- InProTher
- Institute for Bioengineering of Catalonia
- Institute of Medical Science Research Hospital
- Institute of Translational Health Sciences
- International AIDS Vaccine Initiative (IAVI)
- InvivoGen
- IPPOX Foundation
- IQVIA (formerly known as QuintilesIMS)
- Iveric Bio
- JAFRAL Biosolutions
- Jansen Pharmaceuticals
- Jiangsu Puxin Biomedicine
- Juno Therapeutics
- Juventas Cell Therapy
- JW Therapeutics
- KAEDI
- Kaneka Eurogentec
- Karolinska Institute
- Karolinska University Hospital
- Kavli Institute for Systems Neuroscience
- Kecellitics Biotech
- King's College London
- Kite Pharma (a subsidiary of Gilead Sciences)
- KMD Bioscience
- Kobe Biomedical Innovation Cluster
- Kolon TissueGene
- Kriya Therapeutics
- Krystal Biotech
- Kuur Therapeutics
- Laboratory of Digital Sciences of Nantes
- LakePharma (acquired by Curia)
- Legend Biotech
- Leiden University Medical Centre
- Lentigen Technology
- Leucid Bio
- Leukocare
- Leuven Viral Vector Core (LVVC)
- Lexeo
- LEXEO Therapeutics
- Lion TCR
- Lipigon Pharmaceuticals
- LNBio
- LogicBio Therapeutics
- LOKA Biosciences
- Lokon Pharma
- Lonza
- Louisiana State University School of Veterinary Medicine
- Luina Bio
- Luminous BioSciences
- Lund University
- Lysogene
- Magee-Womens Research Institute
- Maine Medical Center Research Institute (MMCRI)
- MaineHealth Institute for Research
- MaineHealth Institute for Research (MHIR)
- MangoGen Pharma
- Marino Biotechnology
- Mass Biologics
- Massachusetts Eye and Ear
- Massachusetts General Hospital
- MassBiologics
- Matica Biotechnology
- MaxCyte
- Mayflower Bioscience
- Mayo Clinic Cancer Center
- McMaster Immunology Research Centre (MIRC)
- MD Anderson Cancer Institute
- medac
- Medigene
- MedImmune
- MeiraGTx
- Memorial Sloan Kettering Cancer Center
- Merck
- MicroBiopharm Japan
- Microsoft
- Mila’s Miracle Foundation
- MilliporeSigma
- Milo Biotechnology
- Miltenyi Biotec
- Minerva Biotechnologies
- MingJu Therapeutics
- Mitsubishi Tanabe Pharma
- Moderna
- Molecular Diagnostic Services
- MolMed (acquired by AGC Biologics)
- Momotaro-Gene
- MultiVir
- Mustang Bio
- Mycenax Biotech
- Myeloma Crowd
- Nanjing Bioheng Biotech
- Nantes Gene Therapy Institute
- Naobios (a subsidiary of Clean Biologics)
- National Cancer Institute
- National Center for Advancing Translational Sciences
- National Human Genome Research Institute
- National Institute of Allergy and Infectious Diseases
- National Institute of Environmental Health Sciences
- National Institute of Neurodegenerative Disorders and Stroke
- Nationwide Children's Hospital
- Naval Medical Research Center
- Neurimmune
- NeuroCure
- Neurophth Therapeutics
- Neuroscience Center Zurich
- New Jersey Innovation Institute (NJII)
- NewLink Genetics
- NHS Blood and Transplant
- Nikon CeLL innovation
- Noga therapeutics
- Norgen Biotek
- Northern RNA
- NorthX Biologics
- Nouscom
- Novartis
- Novartis Gene Therapies
- Novasep
- Novavax
- OBiO Technology
- Odylia Therapeutics
- OHSU Casey Eye Institute
- Okairos
- Omnia Biologics
- OmniaBio
- Oncolys BioPharma
- OncoSenX
- ORCA Therapeutics
- Oregon Health & Science University
- Orgenesis
- Otonomy
- Oxford BioMedica
- Oxford Genetics
- OXGENE
- OZ Biosciences
- PackGene Biotech
- PACT Pharma
- Pall Biotech
- Paragon Bioservices
- Paras Biopharmaceuticals
- Passage Bio
- PeriphaGen
- PerkinElmer
- PersonGen BioTherapeutics
- Peter MacCallum Cancer Centre
- Pfizer
- PharmaCell
- pHion Therapeutics
- PhorMed
- Pinze Lifetechnology
- PlasmidFactory
- Porton Advanced Solutions
- Poseida Therapeutics
- Precigen
- Precision BioSciences
- Pregene Biotechnology
- Prevail Therapeutics
- Prime Vector Technologies
- ProBioGen
- PROGEN
- Progenics Pharmaceuticals
- ProMab Biotechnologies
- Protheragen
- Provecs Medical
- PsiOxus Therapeutics
- PTC Therapeutics
- Puresyn
- Quethera (acquired by Astellas Pharma)
- Regeneron Pharmaceuticals
- REGENXBIO
- ReiThera
- Renova Therapeutics
- Rentschler Biopharma
- Resilience
- Richter-Helm BioLogics
- Roche
- Rocket Pharmaceuticals
- Roswell Park Comprehensive Cancer Center
- Rznomics
- SAB Technology
- SAFC
- Saiba Biotech
- Salk
- Sanford Burnham Prebys
- Sangamo Therapeutics
- Sanofi
- Santen Pharmaceutical
- Sarepta Therapeutics
- Sartorius Stedim Biotech
- Scancell
- Scorpius BioManufacturing
- Seattle Children's Research Institute (SCRI)
- Selecta Biosciences
- Sensorion
- Senti Biosciences
- Servier
- Shanghai Biomed-Union Biotechnology
- Shanghai Bioray Laboratory
- Shanghai Cell Therapy Group
- Shanghai GeneChem
- Shanghai Longyao Biotechnology
- Shanghai PerHum Therapeutics
- Shanghai Sunway Biotech
- Shanghai Unicar-Therapy Bio-medicine Technology
- Shenzhen Binde Biotechnology
- Shenzhen Sibiono GeneTech
- SignaGen Laboratories
- SillaJen
- Simcere Pharmaceutical
- Sinobioway Cell Therapy
- SIRION Biotech
- Skyline Therapeutics
- Solid Biosciences
- Sorrento Therapeutics
- Southern RNA
- Spark Therapeutics
- SQZ Biotechnologies
- St. Jude Children's Research Hospital
- Stanford University
- Symbiosis Pharmaceutical Services
- Synpromics
- Synthace
- System Biosciences
- Takara Bio
- Takeda Pharmaceutical
- Tamid Bio (a subsidiary of Fortress Biotech)
- Targovax
- Taysha Gene Therapies
- TCR2 Therapeutics
- TCRCure Biopharma
- tebu-bio
- Telethon Institute of Genetics and Medicine (TIGEM)
- Terry Fox Laboratory
- Tessa Therapeutics
- The Beijing Pregene Science and Technology
- The Hong Kong Institute of Biotechnology
- The Hormel Institute
- The Jackson Laboratory
- The Jenner Institute
- The Michael J. Fox Foundation
- The Native Antigen Company
- The University of Queensland
- The University of Tennessee Health Science Center
- The Vector Core, University of North Carolina
- Themis (acquired by Merck)
- TheraBiologics
- TheraVectys
- Thermo Fisher Scientific
- Tianjin Mycure Medical Technology
- Timmune Biotech
- Tmunity Therapeutics
- Tolerion
- Touchlight
- Transgene
- Treadwell Therapeutics
- Treeway
- TriLink BioTechnologies (a subsidiary of Maravai LifeSciences)
- Trizell
- Twist Bioscience
- TxCell
- uBriGene Biosciences
- UC Davis
- UC San Diego School of Medicine
- UK Cystic Fibrosis Gene Therapy Consortium
- Ultragenyx Pharmaceutical
- uniQure
- Univercells
- University Hospital Tuebingen
- University Medical Center Groningen
- University of Adelaide
- University of California
- University of Eastern Finland
- University of Florida
- University of Iowa
- University of Maryland
- University of Michigan Health
- University of Minnesota
- University of North Carolina
- University of Pennsylvania
- University of Pittsburgh
- University of South Carolina School of Medicine
- University of Southampton
- University of Tennessee Health Science Center
- University of Tokyo
- University of Virginia School of Medicine
- Urovant Sciences
- USC School of Pharmacy
- UT Southwestern Medical Center
- Vaccine Manufacturing and Innovation Centre (VMIC)
- Vaccitech
- VBL Therapeutics
- VCN Biosciences
- Vectalys
- Vector Biolabs
- Vector BioMed
- VectorBuilder
- Vecura
- Versiti Blood Research Institute
- VGXI
- Vibalogics (acquired by Recipharm)
- Vigene Biosciences (acquired by Charles River Laboratories)
- Vineti
- Viralgen (a subsidiary of Asklepios BioPharmaceutical)
- Virapur
- ViraQuest
- ViroCell Biologics
- ViroMed
- Virovek
- VIVEbiotech
- Voyager Therapeutics
- VVector Bio
- VWR (a subsidiary of Avantor)
- Wacker Biotech
- Waisman Biomanufacturing
- Washington University School of Medicine
- Wellington Zhaotai Therapies
- WhiteLab Genomics
- Wuhan Bio-Raid Biotechnology
- Wuhan Sian Medical Technology
- WuXi AppTec
- Wyvern Pharmaceuticals
- Xiangxue Life Sciences
- Xpress Biologics
- XyloCor Therapeutics
- Xyphos Biosciences
- Yake Biotechnology
- Yonsei University Health System
- Yposkesi
- Yufan Biotechnologies
- Ziopharm Oncology
Methodology
LOADING...
